1887

Journal of Medical Microbiology logo

Volume 62, Issue 4

activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against strains evaluated by kill kinetics Free

Abstract

This study was designed to investigate the killing activity of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against 12 strains by kill kinetics over time. MIC values were determined by Etest and by agar dilution. strains were divided according to their MIC values into two groups: one group with strains with MIC <8.0 µg ml and one group with strains with MIC ≥8.0 µg ml. For kill kinetics over time, the strains with MIC <8.0 µg ml were incubated with the antibiotics at 0.5, 1, 2 and 4 times their MIC values. The strains with MIC ≥8.0 µg ml were incubated with 0.5, 1, 2, and 4 times the maximum achievable concentrations of the antibiotics in human plasma ( ). Among the strains with MIC <8.0 µg ml levofloxacin and gatifloxacin showed equal efficacy. The growth of the strains with MIC ≥8.0 µg ml was barely affected by levofloxacin, while gatifloxacin had bactericidal action when concentrations of 4× were used. Moxifloxacin was more effective against both groups of strains compared with levofloxacin and gatifloxacin. Garenoxacin was the most active agent against all strains investigated. Due to the varying activity of the quinolones against obligate anaerobes the treatment with quinolones of patients with intra-abdominal infections needs intensive scrutiny.

  • Received:
  • Accepted:
  • Published Online:
© 2013 SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.053280-0
2013-04-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/4/576.html?itemId=/content/journal/jmm/10.1099/jmm.0.053280-0&mimeType=html&fmt=ahah

References

  1. Betriu C., Culebras E., Gómez M., López F., Rodríguez-Avial I., Picazo J. J. 2008; Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. Antimicrob Agents Chemother 52:2686–2690 [View Article][PubMed]
     [Google Scholar]
  2. CLSI 2007 Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard, 7th edn. M11-A7. Wayne, PA: Clinical and Laboratory Standards Institute
  3. EUCAST 2012 Breakpoint tables for interpretation of MICs and zone diameters, Version 2.0, valid from 2012-01-01 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf
  4. European Medicines Agency 2007 Press Release. Schering-Plough Europe withdraws its marketing authorisation application for Garenoxacin mesylate http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000747/wapp/Initial_authorisation/human_wapp_000066.jsp&mid=WC0b01ac058001d128&source=homeMedSearch&category=human
  5. Fille M., Mango M., Lechner M., Schaumann R. 2006; Bacteroides fragilis group: trends in resistance. Curr Microbiol 52:153–157 [View Article][PubMed]
     [Google Scholar]
  6. Fünfstück R., Wagenlehner F. M., Olschläger T., Naber K. G. 2012; [Urinary tract infections: cystitis, pyelonephritis, urosepsis]. Dtsch Med Wochenschr 137:198–201 (in German) [PubMed] [CrossRef]
     [Google Scholar]
  7. Gajjar D. A., Bello A., Ge Z., Christopher L., Grasela D. M. 2003; Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 47:2256–2263 [View Article][PubMed]
     [Google Scholar]
  8. Golan Y., McDermott L. A., Jacobus N. V., Goldstein E. J., Finegold S., Harrell L. J., Hecht D. W., Jenkins S. G., Pierson C. other authors 2003; Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 52:208–213 [View Article][PubMed]
     [Google Scholar]
  9. Goldstein E. J., Citron D. M., Tyrrell K. L., Merriam C. V. 2011a; Activity of garenoxacin against 536 unusual anaerobes including 128 recovered from acute pelvic infections. Diagn Microbiol Infect Dis 70:131–136 [View Article][PubMed]
     [Google Scholar]
  10. Goldstein E. J., Solomkin J. S., Citron D. M., Alder J. D. 2011b; Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis 53:1074–1080 [View Article][PubMed]
     [Google Scholar]
  11. Hamasuna R., Takahashi S., Kiyota H., Yasuda M., Hayami H., Arakawa S., Tomono K., Matsumoto T. 2011; Effect of gatifloxacin against Mycoplasma genitalium-related urethritis: an open clinical trial. Sex Transm Infect 87:389–390 [View Article][PubMed]
     [Google Scholar]
  12. Hedberg M., Nord C. E. ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria 2003; Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 9:475–488 [View Article][PubMed]
     [Google Scholar]
  13. Hosaka M., Yasue T., Fukuda H., Tomizawa H., Aoyama H., Hirai K. 1992; In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 36:2108–2117 [View Article][PubMed]
     [Google Scholar]
  14. Kleinkauf N., Ackermann G., Schaumann R., Rodloff A. C. 2001; Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 45:1896–1899 [View Article][PubMed]
     [Google Scholar]
  15. Liu H. H. 2010; Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 33:353–369 [View Article][PubMed]
     [Google Scholar]
  16. Liu H., Mulholland S. G. 2005; Appropriate antibiotic treatment of genitourinary infections in hospitalized patients. Am J Med 118:Suppl. 7A14S–20S [View Article][PubMed]
     [Google Scholar]
  17. Lubasch A., Keller I., Borner K., Koeppe P., Lode H. 2000; Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 44:2600–2603 [View Article][PubMed]
     [Google Scholar]
  18. Mueller M., de la Peña A., Derendorf H. 2004; Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48:369–377 [View Article][PubMed]
     [Google Scholar]
  19. Naber K. G., Adam D. 1998; Classification of fluoroquinolones. Int J Antimicrob Agents 10:255–257[PubMed] [CrossRef]
     [Google Scholar]
  20. Nagy E., Urbán E., Nord C. E. ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria 2011; Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 17:371–379 [View Article][PubMed]
     [Google Scholar]
  21. Nguyen M. H., Yu V. L., Morris A. J., McDermott L., Wagener M. W., Harrell L., Snydman D. R. 2000; Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 30:870–876 [View Article][PubMed]
     [Google Scholar]
  22. Odenholt I., Cars O. 2006; Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 58:960–965 [View Article][PubMed]
     [Google Scholar]
  23. Ohsaki Y., Morita K., Takeda H., Kishino S., Okumura S., Fujiuchi S. 2010; Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections. Int J Antimicrob Agents 35:603–605 [View Article][PubMed]
     [Google Scholar]
  24. Schaumann R., Rodloff A. C. 2007; Activities of quinolones against obligately anaerobic bacteria. Antiinfect Agents Med Chem 6:49–56 [View Article]
     [Google Scholar]
  25. Schaumann R., Blatz R., Beer J., Ackermann G., Rodloff A. C. 2004; Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli . J Antimicrob Chemother 53:318–324 [View Article][PubMed]
     [Google Scholar]
  26. Schaumann R., Goldstein E. J., Forberg J., Rodloff A. C. 2005a; Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 54:749–753 [View Article][PubMed]
     [Google Scholar]
  27. Schaumann R., Petzold S., Fille M., Rodloff A. C. 2005b; Inducible metronidazole resistance in nim-positive and nim-negative Bacteroides fragilis group strains after several passages metronidazole containing Columbia agar plates. Infection 33:368–372 [View Article][PubMed]
     [Google Scholar]
  28. Schaumann R., Funke M., Janssen E., Rodloff A. C. 2012; In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics. Antimicrob Agents Chemother 56:3413–3416 [View Article][PubMed]
     [Google Scholar]
  29. Stass H., Rink A. D., Delesen H., Kubitza D., Vestweber K. H. 2006; Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 58:693–696 [View Article][PubMed]
     [Google Scholar]
  30. Stein G. E., Goldstein E. J. 2006; Fluoroquinolones and anaerobes. Clin Infect Dis 42:1598–1607 [View Article][PubMed]
     [Google Scholar]
  31. Stratton C. W., Weeks L. S., Aldridge K. E. 1987; Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group. J Clin Microbiol 25:645–649[PubMed]
     [Google Scholar]
  32. Tanigawara Y., Nozawa K., Tsuda H. 2012; Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation. Eur J Clin Pharmacol 68:39–53 [View Article][PubMed]
     [Google Scholar]
  33. Tarshis G. A., Miskin B. M., Jones T. M., Champlin J., Wingert K. J., Breen J. D., Brown M. J. 2001; Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother 45:2358–2362 [View Article][PubMed]
     [Google Scholar]
  34. Tillotson G. S. 1996; Quinolones: structure–activity relationships and future predictions. J Med Microbiol 44:320–324 [View Article][PubMed]
     [Google Scholar]
  35. Wexler H. M. 2007; Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 20:593–621 [View Article][PubMed]
     [Google Scholar]
  36. Wilson S. E., Huh J. 1997; In defense of routine antimicrobial susceptibility testing of operative site flora in patients with peritonitis. Clin Infect Dis 25:Suppl. 2S254–S257 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.053280-0
Loading
In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics
J. Med. Microbiol. 62, 576 (2013); https://doi.org/10.1099/jmm.0.053280-0
/content/journal/jmm/10.1099/jmm.0.053280-0
/content/journal/jmm/10.1099/jmm.0.053280-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error